Evaluation of efficacy,safety and economy of different proportions of piperacillin tazobactam for compli-cated urinary tract infection
OBJECTIVE To explore the efficacy,safety and economy of different ratios of domestic piperacillin tazobactam(PT)for complicated urinary tract infection(cUTI)to provide references for clinical rational drug use and proper health decision-making.METHODS This was a multi-center retrospective cohort study at 9 tertiary general hospitals in Guizhou Province.Between January 2020 and December 2022,cUTI patients received different ratios of PT as exposure factors.Confounding fac-tors such as age,nationality,co-morbidity and therapeutic duration were controlled by propensity score matching(PSM).Effi-cacy,safety and economy of two groups of PT were evaluated.RESULTS Among 881 eligible cUTI patients,two groups of PT(8∶1,n=796)and PT(4∶1,n=85)were assigned.After PSM,231 cases were successfully matched and divided into two groups of observation(n=161)and control(n=70).And all variables were matched evenly(P＞0.05).Clinical efficacy of PT(8∶1)was better than that of PT(4∶1)with statistically significant difference(P=0.009).No significant inter-group difference existed in adverse reactions(P=0.605).Total therapeutic expense of PT(8∶1)was lower than that of PT(4∶1).There was sta-tistically significant difference(P＜0.001).CONCLUSION PT(8∶1)and PT(4∶1)have comparable safety for cUTI.How-ever,piperacillin tazobactam(8∶1)is more efficacious and economical.
NETL
NSTL
万方数据
